Bioinformatics and Biostatistics Core
生物信息学和生物统计学核心
基本信息
- 批准号:10441507
- 负责人:
- 金额:$ 25.16万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2020
- 资助国家:美国
- 起止时间:2020-09-22 至 2025-06-30
- 项目状态:未结题
- 来源:
- 关键词:AddressAdverse eventBasic ScienceBioinformaticsBiometryBiostatistics CoreClinicalClinical DataClinical ResearchClinical SciencesClinical TrialsCollaborationsCollectionCommunicationComputersComputing MethodologiesConsultConsultationsDataData AnalysesDatabasesDevelopmentEmploymentEnsureExperimental DesignsFacultyFox Chase Cancer CenterFundingFutilityGoalsHead and Neck CancerHead and neck structureIndividualInformaticsInvestigationLaboratoriesLeadershipMalignant NeoplasmsManuscriptsMedicineMethodologyMethodsMonitorMonitoring Clinical TrialsPatient CarePhysiciansPlayPoliciesPopulationPopulation SciencesPopulation StudyPrevention strategyPrivacyProceduresProgram DevelopmentPublicationsRandomizedReproduction sporesResearchResearch PersonnelResearch ProposalsResourcesRoleSafetySample SizeScheduleScienceSequence AnalysisServicesSuggestionSystemTimeTranslational ResearchWorkWritingYale Cancer Centerbasecareer developmentdata managementdata miningdesignexperimental studyfrontiergenomic datainnovationmeetingsmembermultidimensional datanext generationnext generation sequencingpre-clinicalprogramsresearch and developmenttherapy resistanttooltranslational studytreatment strategyweb-accessible
项目摘要
Project Summary
The goal of the Biostatistics and Bioinformatics Core (Core C) is to address the statistical design and analysis
needs of the Yale SPORE in Head and Neck Cancer (YHN-SPORE) Projects, the Cores, the Developmental
Research Program (DRP), and the Career Development Program (CDP). To accomplish this goal we have
assembled a highly interactive team of cancer biostatisticians and bioinformaticians who will work
collaboratively with basic, clinical, translational, and population science researchers to advance the frontiers of
cancer medicine. The specific aims of the Biostatistics and Bioinformatics Core are:
Aim 1: Provide collaboration and consulting in the design, execution, monitoring and analysis of basic,
translational, population, and clinical studies for YHN-SPORE.
Aim 2: Oversee and coordinate the collection, management, and analysis of data. Ensure that data collected
on all YHN-SPORE studies are of high quality, are evaluated with bioinformatic and statistical rigor, are
accessible within SPORE-affiliated collaborative groups, ultimately enabling the widest accessibility that is
appropriate given publication and privacy concerns.
For Aim 1, the Core will work closely with the investigators to analyze clinical trial and pre-clinical data, next
generation sequencing data, and bioinformatics data mining. Services provided by the Core will range from
planning and design activities to consulting on specific analytic questions. The Core will address the analytic
and informatics questions arising from the YHN-SPORE projects. The Core will rigorously design and monitor
clinical trials for safety, efficacy and futility. The Core will schedule regular meetings with the YHN-SPORE
investigators, and maintain an open-door policy for any biostatistical and bioinformatics questions. The Core
will conduct interim and final analyses, develop new statistical and bioinformatics methodology as needed,
provide timely suggestions to YHN-SPORE investigators, and thus play an important role in the entire study.
Biostatistics and Bioinformatics is also a key partner in the YHN-SPORE with representation on their Senior
Leadership Team and participation in all core meetings. For Aim 2, The Core will work with the Yale Cancer
Center (YCC), Yale Center for Analytical Sciences (YCAS), Fox Chase Cancer Center (FCCC) and its
quantitative cores to facilitate communication among YHN-SPORE researchers, creating and implementing
web-accessible databases for collecting, storing and accessing the various types of data (e.g. laboratory,
clinical, population, and genomic data) that will be generated for the YHN-SPORE projects. The Core is highly
integrated with the projects, and will have regular meetings with project investigators, as well as YCAS data
managers, to evaluate the data generated from the studies and ensure accurate and up-to-date data
management.
项目总结
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Jeffrey Peter Townsend其他文献
Jeffrey Peter Townsend的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Jeffrey Peter Townsend', 18)}}的其他基金
Evolutionary multispecies transcriptomics to reveal genes conferring pathogenicity within Leptospira spp
进化多物种转录组学揭示钩端螺旋体致病性基因
- 批准号:
10283483 - 财政年份:2021
- 资助金额:
$ 25.16万 - 项目类别:
Evolutionary multispecies transcriptomics to reveal genes conferring pathogenicity within Leptospira spp
进化多物种转录组学揭示钩端螺旋体致病性基因
- 批准号:
10448321 - 财政年份:2021
- 资助金额:
$ 25.16万 - 项目类别:
相似海外基金
Planar culture of gastrointestinal stem cells for screening pharmaceuticals for adverse event risk
胃肠道干细胞平面培养用于筛选药物不良事件风险
- 批准号:
10707830 - 财政年份:2023
- 资助金额:
$ 25.16万 - 项目类别:
Hospital characteristics and Adverse event Rate Measurements (HARM) Evaluated over 21 years.
医院特征和不良事件发生率测量 (HARM) 经过 21 年的评估。
- 批准号:
479728 - 财政年份:2023
- 资助金额:
$ 25.16万 - 项目类别:
Operating Grants
Analysis of ECOG-ACRIN adverse event data to optimize strategies for the longitudinal assessment of tolerability in the context of evolving cancer treatment paradigms (EVOLV)
分析 ECOG-ACRIN 不良事件数据,以优化在不断发展的癌症治疗范式 (EVOLV) 背景下纵向耐受性评估的策略
- 批准号:
10884567 - 财政年份:2023
- 资助金额:
$ 25.16万 - 项目类别:
AE2Vec: Medical concept embedding and time-series analysis for automated adverse event detection
AE2Vec:用于自动不良事件检测的医学概念嵌入和时间序列分析
- 批准号:
10751964 - 财政年份:2023
- 资助金额:
$ 25.16万 - 项目类别:
Understanding the real-world adverse event risks of novel biosimilar drugs
了解新型生物仿制药的现实不良事件风险
- 批准号:
486321 - 财政年份:2022
- 资助金额:
$ 25.16万 - 项目类别:
Studentship Programs
Pediatric Adverse Event Risk Reduction for High Risk Medications in Children and Adolescents: Improving Pediatric Patient Safety in Dental Practices
降低儿童和青少年高风险药物的儿科不良事件风险:提高牙科诊所中儿科患者的安全
- 批准号:
10676786 - 财政年份:2022
- 资助金额:
$ 25.16万 - 项目类别:
Pediatric Adverse Event Risk Reduction for High Risk Medications in Children and Adolescents: Improving Pediatric Patient Safety in Dental Practices
降低儿童和青少年高风险药物的儿科不良事件风险:提高牙科诊所中儿科患者的安全
- 批准号:
10440970 - 财政年份:2022
- 资助金额:
$ 25.16万 - 项目类别:
Improving Adverse Event Reporting on Cooperative Oncology Group Trials
改进肿瘤学合作组试验的不良事件报告
- 批准号:
10642998 - 财政年份:2022
- 资助金额:
$ 25.16万 - 项目类别:
Planar culture of gastrointestinal stem cells for screening pharmaceuticals for adverse event risk
胃肠道干细胞平面培养用于筛选药物不良事件风险
- 批准号:
10482465 - 财政年份:2022
- 资助金额:
$ 25.16万 - 项目类别:
Expanding and Scaling Two-way Texting to Reduce Unnecessary Follow-Up and Improve Adverse Event Identification Among Voluntary Medical Male Circumcision Clients in the Republic of South Africa
扩大和扩大双向短信,以减少南非共和国自愿医疗男性包皮环切术客户中不必要的后续行动并改善不良事件识别
- 批准号:
10191053 - 财政年份:2020
- 资助金额:
$ 25.16万 - 项目类别: